N/A N=38 Age-related Hearing Loss and Lexical Disorders
Alzheimer Disease · Presbycusis · Lexical Syntactic Disorder
Primary: Link Between Lack of Word and Presbycusis — 38; 38.5; 23; 21.5 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=23 Connecting Contact Lenses and Digital Technology
Asthenopia · Contact Lenses · Ocular Accommodation
Primary: Subjective Symptom Improvement — 153.9; 100.7; 272.13 score on a scale — p=0.07
Phase 2 N=7 Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer
Head and Neck Cancer · Head and Neck Squamous Cell Carcinoma
Primary: Progression — 1 Participants
Phase 4 N=30 Naturalistic Study, Comparison of Divalproex Extended Release (ER) and Quetiapine for Adults With Acute Mania or Mixed Episodes
Bipolar Disorder
Primary: Primary Measure: Young Mania Rating Scale (YMRS) Primary Endpoint: Day 7 — 14.8; 13.9 units on a scale
Phase 2 N=148 Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)
Leukemia, Myelogenous, Chronic
Primary: Participants With Complete Molecular Response (Molecular CR) — 23 Participants
N/A N=53 Breastfeeding Support and Weight Management for Black Women
Breastfeeding · Weight Loss
Primary: Number of Participants Still Breastfeeding at 20 Weeks Postpartum — 9; 8 Participants
Phase 3 N=207 A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease
Behçet's Syndrome
Primary: Area Under the Curve (AUC) for the Number of Oral Ulcers From Baseline Through Week 12 (AUC W0-12) — 222.14; 129.54 Ulcers*days — p=<0.0001
N/A N=23 The Effects of the Water Drinking Test on Intraocular Pressure
Glaucoma
Primary: 24-hour IOP Patterns
N/A N=91 Executive Functioning in TBI From Rehabilitation to Social Reintegration: COMPASS
Traumatic Brain Injury · Post-Traumatic Stress Disorder
Primary: Change From Baseline in Community Reintegration for Injured Service Members at 2 Months — 40.22; 37.79 score on a scale
N/A N=132 Motivational Interviewing to Prevent Suicide in High Risk Veterans
Suicidal Ideation · Treatment Engagement
Primary: Number of Participants With Suicidal Ideation — 16; 19; 38; 17 Participants — p=.054
Phase 1 N=19 A Study of LY2940680 in Japanese Participants With Advanced Cancers
Neoplasm Metastasis
Primary: Number of Participants With LY2940680 Dose-Limiting Toxicities (DLT) — 0; 0; 3 Participants
Phase 2 N=33 A Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Participants With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naive
Hepatitis C, Chronic
Primary: Number of Participants With Adverse Events (AEs) — 15; 9 participants
Phase 3 N=61 Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder
Autism Spectrum Disorder
Primary: Treatment Responder — 9; 4 Participants
Phase 3 N=180 Study of the Safety and Efficacy of OmegaD Softgels in the Treatment of Dry Eye Disease
Dry Eye
Primary: Change From Baseline in Tear Break up Time(TBUT ) at Day 84 — 1.45; 1.23 seconds
Phase 2 N=24 A Controlled Trial to Evaluate the Effects of GanedenBC30 on the Immune System
HIV Infection · Gastrointestinal Symptoms
Primary: Effects of Daily Consumption of GanedenBC30 on Immune Function and Gastro-intestinal Issues